Guillain-Barré syndrome after rituximab in a patient with idiopathic thombocytopenic purpura: a causal association?
Raquel
R
Jaso
María
M
Sierra
Jesús
J
Calleja
Carmen
C
Valero
Julio
J
Pascual
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies / Q000187:drug effects / Q000276:immunology; D015984:Causality; D004568:Electrodiagnosis; D020275:Guillain-Barre Syndrome / Q000139:chemically induced* / Q000276:immunology* / Q000503:physiopathology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007155:Immunologic Factors / Q000009:adverse effects; D007165:Immunosuppression Therapy / Q000009:adverse effects; D008297:Male; D010525:Peripheral Nerves / Q000187:drug effects / Q000276:immunology / Q000503:physiopathology; D011241:Prednisone / Q000627:therapeutic use; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D011782:Quadriplegia / Q000139:chemically induced / Q000276:immunology / Q000503:physiopathology; D000069283:Rituximab; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D001323:Autoantibodies; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D000069283:Rituximab; D011241:Prednisone